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“We can no longer count on ‘nature’ to balance conditions of human bodies, nor 
can we assume that there is some fixed, immutable ‘normal human’ ideal that will 
be automatically maintained through time.”
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How can evolutionary medicine inform future 
personalized medicine?
Mutations are inevitable, they must 
be treated
With the chemical instability of the DNA mol-
ecule it is inevitable that mutations occur. In 
the past, when the opportunity for natural selec-
tion was significant [3], many deleterious muta-
tions were removed from the gene pool nearly 
as fast as they arose. At present, and looking to 
the future, in the situation of very significantly 
relaxed selection [4,5], mutations will be accumu-
lating in the human gene pool. Numerous muta-
tions will increase in proportion to the growing 
size of the human population [6]. This increase 
in the number and kinds of mutations presents 
a significant challenge to the future of medical 
practice. Eugenics, which aims at ‘purification’ 
of human genetic material has been thoroughly 
discredited during the 20th century. Thus, the 
only ethically acceptable approach in the future 
will be that of accepting the results of mutations 
as new forms of human physiology, immunol-
ogy and anatomy, and their case-specific treat-
ment. Since mutations are random changes in 
the genetic material, their most probable effect 
on the integrity of a human body is detrimental 
[7]. This poses a challenge for future personalized 
medicine because new variants of genetic mate-
rial will have to be recognized and their, mostly 
detrimental, effects neutralized by case-specific 
treatments.
Immunological uniqueness of 
individuals
Our immune systems react to stimuli experi-
enced during the early stages of our ontogeny. 
Infants and children encounter various envi-
ronmental challenges and their immune sys-
tems ‘learn’ how to respond to them. In our 
highly urbanized environments the suite of 
Evolutionary medicine is based on 
individual variation
Evolutionary medicine is based on the 
Darwinian principle that individual variation 
is sorted in the process of its transmission from 
generation-to-generation by the forces of evo-
lution. These are directional: mutations and 
natural selection; and nondirectional: gene 
flow, inbreeding, genetic drift and assortative 
mating [1]. Evolutionary medicine is relevant for 
personalized medicine since it can foster under-
standing into the relationship between disease 
and human populations. Evolutionary medicine 
can also offer nonproximate reasons as to why 
the body is susceptible to disease. Such aware-
ness may assist towards implementing novel and 
personalized medical treatments.
The essence of the Darwinian principle is 
that each individual is different from other 
individuals and only individuals exist in reality 
while groupings of individuals into categories 
are products of the human mind that may be 
more or less useful for specific practical purposes 
[2]. In terms of evolutionary medicine it means 
that it is inappropriate to apply the same diag-
nostic methods and treatments to all people. 
Medical attention must be individualized. In 
its rudimentary form this principle is observed 
in routine medical practice when blood groups 
are used and specific genetic disorders can be 
recognized (hemoglobinopathies such as sickle 
cell anemia, thalassemia and metabolic prob-
lems such as phenylketonuria). However, with 
the advent of gene sequencing and proteom-
ics, the individualization of treatments and 
diagnostic methods will expand in the future. 
Specific treatments can be designed for individ-
ual patients to provide maximum therapeutic 
results for their genetic and epigenetic makeup.
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antigens that the body of a child encounters 
is rapidly changing, with many traditional 
stimuli, such as internal and external parasites, 
removed by hygienic measures and a host of 
new chemicals introduced by industrial proc-
esses [8]. Moreover, increased travel exposes 
individuals to a greater number of immune 
challenges than in traditional sedentary socie-
ties. Each human being has a different history 
of exposure to stimuli, and thus, a somewhat 
unique immune system. Although our immune 
systems are evolving from generation-to-genera-
tion, they contain a large amount of adaptations 
to ‘traditional’ environments and during indi-
vidual lives our adaptability to new immune 
challenges is limited. This produces allergies 
and hyperimmune responses to stimuli that an 
individual encounters during their life, espe-
cially when changing places of residence and 
working environments. Since individuals are 
variable in their responses to immune system 
stimuli, treatment of particular patients will 
require a personalized approach.
“...only individuals exist in reality while 
groupings of individuals into categories are 
products of the human mind that may be 
more or less useful for specific practical 
purposes.”
Degenerative diseases
With increased longevity ‘degenerative’ diseases 
have become the primary cause of death, over-
taking infectious diseases [9]. Prominent among 
them are those of the circulatory system, osteo-
arthritis and diseases of the CNS. Neoplasms 
are another serious problem. At present, severe 
cases of circulatory diseases, neoplasms and of 
osteoarthritis are treated surgically through 
blood vessel enlargements/replacements, tumor 
removal, joint implants and mechanical stabi-
lization (spinal fusion). Loss of neurons in the 
CNS will probably be treated in the future 
through the use of stem cells. Improvement of 
brain function and of the special sense organs 
will be achieved by brain–machine interactions 
[10]. In the rudimentary form, such machine 
enhancements of special sense organs are 
already available (cochlear implants) or are in 
advanced stages of research (ocular implants). 
Moreover, current research in brain–machine 
interfaces is in the area of motor control [11] and 
inter facing the nervous system parenchyma [10]. 
Each individual has a different life history, and 
thus, a different suite of degenerative problems.
Chemical therapies of degenerative diseases 
are only partially successful. They await future 
improvements in terms of individualization of 
delivery of chemicals to coordinate their impact 
with that of the patient’s own immune system 
and of the precise targeting of anatomical loca-
tions through the use of nanotechnology for 
drug delivery [12]. In both cases, treatments will 
have to be personalized taking into account 
individual immune rhythms and anatomical 
variations in patient’s bodies.
Individual reproductive needs
With the relaxation of natural selection, and 
modernization of living conditions, infertility has 
become a problem. Females often yield to pres-
sures of their careers and postpone having chil-
dren until late in their lives. Birth control, which 
in the 20th century was mostly aimed at preven-
tion of unwanted pregnancies and births, now 
gained a sizeable ‘positive’ element – compensa-
tion of infertility where techniques are applied to 
enhance ability to get pregnant and give birth. It 
is the right of every human being to have prog-
eny. Thus, assistance in reproductive success has 
become an important part of medicine. Having 
children, especially going through the complex 
experience of pregnancy and motherhood, is one 
of the most intimate human endeavors. Each 
patient may be different not only in the biological 
characteristics determining reproductive success 
or problems, but also in psychological approach 
to parenthood. Thus, assisted reproductive 
treatments will also have to be personalized.
“...treatments will have to be personalized 
taking into account individual immune rhythms 
and anatomical variations in patient’s bodies.”
Concern for the future
Helping a patient with a particular ailment may 
perpetuate this ailment in future generations. 
Help should still be provided but in a manner 
that will not have future consequences. We can 
no longer count on ‘nature’ to balance conditions 
of human bodies, nor can we assume that there 
is some fixed, immutable ‘normal human’ ideal 
that will be automatically maintained through 
time. In reality, only individual patients exist and 
modes of their existence will define the entire 
human condition in the future. This is precisely 
where evolutionary medicine can prove to be 
beneficial in offering a much needed heuristic for 
developing a complementary approach to future 
personalized medicine.
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